Photo Credit: Iri-s
The following is a summary of “Incidence of Psoriatic Arthritis in a Primary Care Psoriasis Population in the United Kingdom” published in the November 2024 issue of Rheumatology by Rudge et al.
Researchers conducted a retrospective study to analyze the annual incidence of psoriatic arthritis (PsA) in a UK primary care population with psoriasis (PsO), following patients over 2 years and excluding baseline PsA.
They conducted a multicenter, prospective, 2-arm parallel-group trial (TUDOR; ISRCTN registry: ISRCTN38877516) to assess early identification of PsA via annual rheumatological assessments, termed “Enhanced Surveillance,” vs standard care for patients with PsO in primary care. They reported the incidence of PsA at 12 and 24 months, excluding those with prevalent PsA at baseline.
The results showed that 14 of 511 participants developed PsA during the 12-month screening, resulting in an incidence of 2.74/100 patient-years (PYs; 95% CI 1.32-4.16). At the 24-month visit, another 7 of 444 participants developed PsA, yielding an incidence of 1.58/100 PYs (95% CI 0.42-2.74). The combined incidence over 2 years was 2.20/100 PYs (95% CI 1.27-3.13).
The study concluded that the estimated annual incidence of PsA was 2.20/100 patient-years, consistent with studies using clinical assessments. They indicated that further follow-up of the TUDOR cohort would enhance the exploration of PsA risk factors.
Source: jrheum.org/content/51/11/1092
